OraPro-COVID-19 / iosBio - LARVOL DELTA

Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. (PubMed, World J Virol) - "Additional to their ability to trigger stable, protective immune responses at the sites of pathogenic infection, the development of 'specific' mucosal vaccines targeting coronavirus antigens could be an excellent option for preventing future pandemics. However, their efficacy and safety should be confirmed."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Stabilitech Biopharma joins race to develop Covid-19 vaccine delivering unique double immunity using self-administered capsules - "STABILITECH BIOPHARMA LTD...has announced today that, it is seeking an investment of £6m to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19....Stabilitech’s unique OraPro-COVID-19 capsules contain a freeze-dried COVID-19 vaccine and are thermally stable....Initial animal safety trials have been successfully concluded and the next stage of Stabilitech’s OraPro COVID-19 development is clinical trials....Trials are set to start in June, and a vaccine could be available by the end of the year. To achieve this, Stabilitech requires £6m in funding for the clinical trials and manufacturing the capsule."

Financing • New trial • Preclinical • Infectious Disease • Novel Coronavirus Disease

Stabilitech's COVID-19 vaccine intended to be delivered in a disruptive thermally stable oral capsule (PRNewswire) - "Stabilitech BioPharma Ltd...this morning announces the completion of its COVID-19 Master Viral Seedstock, which it now intends to have manufactured and formulated into its patent protected capsule for oral vaccine delivery. Once approved by the regulatory authorities, Stabilitech will disrupt the vaccine market by producing safe, efficacious, self-administered vaccine capsules that are inexpensive to produce, developed in weeks, thermally stable and can be posted direct to consumer."

Clinical • Infectious Disease • Novel Coronavirus Disease

Stabilitech’s Covid-19 vaccine for oral administration as a revolutionary thermally stable capsule (PRNewswire) - "Stabilitech BioPharma...announced the development of a prototype COVID-19 starting viral stock which it intends to manufacture and administer orally in the form of patented capsules....Once approved by regulatory authorities, the Stabilitech vaccine will shake up the market thanks to its safe and effective self-administered capsules....The Company is currently in talks with a range of investors to finance its assets under development and benefits from the EIS Advance Assurance guarantee from the British tax authorities (HMRC)."

New molecule • Infectious Disease • Novel Coronavirus Disease